Data from various retinal clinical trials suggest that there is a difference in efficacy in anti-VEGF therapies for patients with lower vision, according to a speaker here. During a presentation at ...
It's a daycare procedure and doesn't require hospitalisation. However, it is an expensive treatment. Will my health insurance ...
The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...
DR was graded according to early Treatment Diabetic Retinopathy (ETDRS) criteria. Results: Of 199 subjects, 108 patients (54.3%) suffer from dry eye syndrome. Although dry eye syndrome was more ...
Highlighting the event is the immersive simulation, “Seeing Beyond the Ordinary and Repairing Damages,” led by world-renowned ...
Diabetes affects millions worldwide, and while most know about its impact on blood sugar and organ health, vision loss ...
The implementation of AIDRSS offers transformative implications for DR screening in India, particularly in rural and ...
About AXPAXLI AXPAXLI™ (axitinib intravitreal injection, also known as OTX-TKI) is an investigational, bioresorbable, hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase ...
Diabetic retinopathy is a serious concern for people dealing with diabetes. Detecting diabetic retinopathy poses significant challenges, requiring skilled professionals, extensive manual image ...
Diabetes extends far beyond blood sugar management, affecting vital organs throughout the body. This chronic condition, ...
Insurance coverage for intravitreal injections, an essential treatment for diabetic retinopathy, depends on the specific terms and conditions of an individual’s health insurance policy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback